End-stage hemolytic rate of leukocyte-reduced RBCs in additive solution: a 5-year retrospective study / 中国输血杂志
Chinese Journal of Blood Transfusion
;
(12): 1157-1159, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-1004079
ABSTRACT
【Objective】 To evaluate the suitability of current quality standard for end-stage hemolytic rate required by Quality Requirements for Whole Blood and Blood Components in Taiyuan through a 5- year retrospective analysis of leukocyte-reduced RBCs in additive solution in Taiyuan Blood Center. 【Methods】 A total of 240 packs of leukocyte-reduced RBCs in additive solution were collected from January 2007 to December 2021. Hb concentration, hematocrit(Hct) and free Hb in supernatant at end-stage were detected to measure the hemolytic rate. And the hemolytic rate was then compared with the current standard(0.8%) to analyze whether statistical differences existed. 【Results】 The hemolytic rate of leukocyte-reduced RBCs in additive solution were 0.109±0.123 in 2017, 0.113±0.085 in 2018, 0.121±0.076 in 2019, 0.101±0.057 in 2020, and 0.128±0.089 in 2021, with no significant difference among each other (P>0.05). And 97.5% of the products showed an end-stage hemolytic rate below 0.4%, 0.83% among 0.6%~0.7%, and none over the standard of 0.8%. 【Conclusion】 The current national standard for end-stage hemolytic rate of leukocyte-reduced RBCs in additive solution might not be suitable for blood quality control in Taiyuan, and a much stricter criteria should be considered.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Blood Transfusion
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS